A Pilot Study of Lithium in Progressive Multiple Sclerosis

Phase 1/2 Completed 23 enrolled VA Office of Research and Development

RandomizedCrossoverSingle-blindTreatment

Summary

The purpose of this study is to determine whether lithium carbonate is safe, well-tolerated, and effective at treating progressive forms of multiple sclerosis.

Timeline

Start: 2011-05
Primary completion: 2015-08
Completion: 2015-12

Outcome

Missed primary endpoint

paper For the 17 who completed the trial, change in PBVC on lithium (+0.107) did not significantly differ from the observation period (-0.355, p = 0.346). PMID 32760832 ↗

registry Lithium vs Observation; p = 0.346; t-test, 2 sided NCT01259388 ↗

Publications

Rinker JR 2nd, Meador WR, King P. Randomized feasibility trial to assess tolerance and clinical effects of lithium in progressive multiple sclerosis. Heliyon. 2020 Jul 28;6(7):e04528. doi: 10.1016/j.heliyon.2020.e04528. eCollection 2020 Jul.

Drugs

Evaluation	Drug	Modality	Dose	Route
Subject	Lithium Carbonate	Unknown	150 mg	—
Subject	Lithium Carbonate	Unknown	300 mg	—